Outset Medical Q4 revenue $29.5M, beats guidance; 2025 outlook $115-125M revenue, high-30% gross margin

Outset Medical, Inc.

2024-FY EPS reported -$2.46 revenue$113,689,000

Q4 revenue $29.5M (+3% QoQ, -3% YoY); full-year $113.7M, beating prior guidance.
Q4 GAAP gross margin 36.5% (37.7% non-GAAP), up 11pp YoY; recurring revenue up 21% to $83.9M in 2024.
Q4 net loss $25.6M ($0.49/sh) vs $38.6M ($0.77/sh) YoY; non-GAAP loss $19.3M ($0.37/sh).
Tablo installed base ~6,000 consoles (+10% in 2024); cash $162M at yr-end, ~$210M after Jan 2025 financing.
2025 guidance: revenue $115-125M, non-GAAP gross margin high-30% range; cash burn <$50M vs $103M in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.